A Phase 2 interventional study of Sonelokimab and Placebo in Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics AG. Completed at 42 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by MoonLake Immunotherapeutics AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Arthritis, Psoriatic with a site in Poland — 6 open to participants now, 25 under way, 18 of them phase 3. Arthritis, Psoriatic · Poland.
Among the 92 studies in Arthritis, Psoriatic with a site in Poland, this one is the 66th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 2, and was the 74th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →6 of the 92 studies in Arthritis, Psoriatic with a site in Poland are open now. Recruiting first, the newest first:
Takeda · Sites in Poland, United States, Argentina and 17 more countries
Ages 18+
UCB Biopharma SRL · Sites in Poland, United States, Bulgaria and 3 more countries
Ages 18+
AbbVie · Sites in Poland, United States, Canada and 3 more countries
Ages 18+
AbbVie · Sites in Poland, Argentina, Austria and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 15 more countries
Ages 3+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 23 · Phase 3 63 · Phase 4 5
First in 2003; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 399 across the 90 interventional studies, 1,005 across the 2 observational. Of the 66 that completed or were terminated, 54 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 92 have an industry lead sponsor. The 10 most frequent:
MoonLake Immunotherapeutics AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
MoonLake Immunotherapeutics AG has 4 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
9 of the studies in Arthritis, Psoriatic with a site in Poland that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 9 to your calendar (.ics) → With an account.
Among the 92 studies in Arthritis, Psoriatic with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.
Patients will be randomized to receive one of three sonelokimab treatment regimes, adalimumab or placebo. Primary efficacy evaluation will take place at Week 12. Patients will be allocated to a further 12 weeks of treatment with sonelokimab or adalimumab based on response assessment at week 12. In certain countries, treatment will end at week 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 1
Drug: Sonelokimab
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 2
Drug: Sonelokimab
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 3
Drug: Sonelokimab
Subjects randomized to this arm will receive placebo
Drug: Placebo
Subjects randomized to this arm will receive adalimumab
Drug: Adalimumab
randomized treatment; parallel group
Also known as: M1095
randomized treatment; parallel-group
randomized treatment; parallel-group
Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12
The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) participant's assessment of arthritis pain (PtAAP) on a Visual Analog Scale (VAS, no pain =0 to severe pain =100); 2) participant's global assessment of disease activity (PtGADA) on a VAS (very well =0 to very poor =100); 3) physician's global assessment of disease activity (phGADA) on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) high sensitivity C-reactive protein (hs-CRP, decrease indicates improvement). A non-responder imputation (NRI) method was used for missing data.
Time frame: At Week 12
Percentage of Participants Achieving an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, and 8 and 12
The ACR20 response criteria was a response of at least 20% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 20% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data. ACR20 response rate at Week 12 was analyzed as a key secondary outcome measure.
Time frame: At Weeks 2, 4, 8, and 12
Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 4, 8 and 12, in Participants With Psoriasis Involving at Least 3% Body Surface Area (BSA) at Baseline
The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI90 response was defined as greater than or equal to 90% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data. PASI90 response at Week 12 was analyzed as a key secondary outcome measure.
Time frame: At Weeks 4, 8, and 12
Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, and 8
The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.
Time frame: At Weeks 2, 4, and 8
Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Weeks 2, 4, 8, and 12
The ACR70 response criteria was a response of at least 70% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 70% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.
Time frame: At Weeks 2, 4, 8, and 12
Percentage of Participants Achieving Minimal Disease Activity at Week 12
Minimal disease activity was defined as meeting 5 of the following 7 criteria: tender joint count (68 joints) ≤1; swollen joint count (66 joints) ≤1; psoriasis area and severity index ≤1 or psoriasis affecting ≤1% of body surface area; PtAAP ≤15 on a VAS (0 = no pain to 100 = severe pain); PtGADA ≤20 on a VAS (0 = very well to 100 = very poor); HAQ-DI ≤0.5 (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and Leeds Enthesitis Index (LEI) ≤1 (overall score ranging from 0 to 6, with higher scores indicating greater disease severity). An NRI method was used for missing data.
Time frame: At Week 12
Percentage of Participants Who Achieved a PASI75 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline
The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI75 response was defined as greater than or 75% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.
Time frame: At Week 12
Percentage of Participants Achieving a PASI100 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline
The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI100 response was defined as 100% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.
Time frame: At Week 12
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 12
The mNAPSI is a tool to assess psoriatic nail involvement. Three groups of features (pitting, onycholysis, and oil-drop dyshromia and crumbling) for each fingernail are graded on a scale from 0 to 3. Four features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) are graded as either present (1) or absent (0) in each fingernail. The total score was calculated by summing the score for each feature and each fingernail and ranged from 0 to 130, with higher scores indicating greater nail disease. A negative change from baseline indicated an improvement in nail disease.
Time frame: Baseline and Week 12
Participants were enrolled in 8 countries in the United States (US) and European Union (EU). The trial included a screening period of up to 4 weeks, a 12-week placebo-controlled treatment period (Part A), a 12-week active treatment period (Part B), and safety follow-up period of 8 weeks (± 7 days) after last dose of trial treatment (or 12 weeks \[± 7 days\] for participants enrolled in Czech Republic). In the US, only Part A was conducted, whereas in the EU, Parts A and B were conducted.
| Milestone | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Part B: Placebo to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 60 mg Without Induction to Sonelokimab 60 mg Q4W | Part B: Sonelokimab 60 mg Without Induction to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 60 mg With Induction to Sonelokimab 60 mg Q4W | Part B: Sonelokimab 60 mg With Induction to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 120 mg With Induction to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 120 mg With Induction to Adalimumab 40 mg Q2W | Part B: Adalimumab 40 mg Q2W to Adalimumab 40 mg Q2W | Part B: Adalimumab 40 mg Q2W to Sonelokimab 120 mg Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 40 | 41 | 41 | 43 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received treatment in part a | 39 | 41 | 41 | 43 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 37 | 41 | 41 | 42 | 41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive treatment | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Part B: Placebo to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 60 mg Without Induction to Sonelokimab 60 mg Q4W | Part B: Sonelokimab 60 mg Without Induction to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 60 mg With Induction to Sonelokimab 60 mg Q4W | Part B: Sonelokimab 60 mg With Induction to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 120 mg With Induction to Sonelokimab 120 mg Q4W | Part B: Sonelokimab 120 mg With Induction to Adalimumab 40 mg Q2W | Part B: Adalimumab 40 mg Q2W to Adalimumab 40 mg Q2W | Part B: Adalimumab 40 mg Q2W to Sonelokimab 120 mg Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 37 | 34 | 5 | 34 | 5 | 36 | 5 | 34 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 35 | 34 | 4 | 34 | 5 | 36 | 4 | 32 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) participant's assessment of arthritis pain (PtAAP) on a Visual Analog Scale (VAS, no pain =0 to severe pain =100); 2) participant's global assessment of disease activity (PtGADA) on a VAS (very well =0 to very poor =100); 3) physician's global assessment of disease activity (phGADA) on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) high sensitivity C-reactive protein (hs-CRP, decrease indicates improvement). A non-responder imputation (NRI) method was used for missing data.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12 | 20.0 | 36.6 | 46.3 | 46.5 | 42.9 |
The ACR20 response criteria was a response of at least 20% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 20% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data. ACR20 response rate at Week 12 was analyzed as a key secondary outcome measure.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Week 2 | 12.5 | 24.4 | 26.8 | 25.6 | 19.0 |
| Week 4 | 30.0 | 48.8 | 51.2 | 48.8 | 54.8 |
| Week 8 | 40.0 | 63.4 | 65.9 | 67.4 | 71.4 |
| Week 12 | 37.5 | 75.6 | 78.0 | 72.1 | 71.4 |
The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI90 response was defined as greater than or equal to 90% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data. PASI90 response at Week 12 was analyzed as a key secondary outcome measure.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Week 4 | 7.7 | 9.4 | 50.0 | 33.3 | 12.5 |
| Week 8 | 7.7 | 53.1 | 69.2 | 33.3 | 31.3 |
| Week 12 | 15.4 | 50.0 | 76.9 | 59.3 | 50.0 |
The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Week 2 | 5.0 | 4.9 | 7.3 | 9.3 | 2.4 |
| Week 4 | 10.0 | 14.6 | 17.1 | 20.9 | 28.6 |
| Week 8 | 10.0 | 22.0 | 26.8 | 23.3 | 35.7 |
The ACR70 response criteria was a response of at least 70% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 70% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Week 2 | 0 | 2.4 | 4.9 | 4.7 | 0 |
| Week 4 | 2.5 | 2.4 | 4.9 | 7.0 | 4.8 |
| Week 8 | 2.5 | 12.2 | 12.2 | 16.3 | 16.7 |
| Week 12 | 12.5 | 24.4 | 29.3 | 25.6 | 28.6 |
Minimal disease activity was defined as meeting 5 of the following 7 criteria: tender joint count (68 joints) ≤1; swollen joint count (66 joints) ≤1; psoriasis area and severity index ≤1 or psoriasis affecting ≤1% of body surface area; PtAAP ≤15 on a VAS (0 = no pain to 100 = severe pain); PtGADA ≤20 on a VAS (0 = very well to 100 = very poor); HAQ-DI ≤0.5 (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and Leeds Enthesitis Index (LEI) ≤1 (overall score ranging from 0 to 6, with higher scores indicating greater disease severity). An NRI method was used for missing data.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Minimal Disease Activity at Week 12 | 20.0 | 26.8 | 43.9 | 37.2 | 35.7 |
The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI75 response was defined as greater than or 75% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a PASI75 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline | 26.9 | 71.9 | 84.6 | 66.7 | 65.6 |
The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI100 response was defined as 100% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.
| Percentage of participants | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants Achieving a PASI100 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline | 15.4 | 37.5 | 57.7 | 48.1 | 43.8 |
The mNAPSI is a tool to assess psoriatic nail involvement. Three groups of features (pitting, onycholysis, and oil-drop dyshromia and crumbling) for each fingernail are graded on a scale from 0 to 3. Four features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) are graded as either present (1) or absent (0) in each fingernail. The total score was calculated by summing the score for each feature and each fingernail and ranged from 0 to 130, with higher scores indicating greater nail disease. A negative change from baseline indicated an improvement in nail disease.
| Score on a scale | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W |
|---|---|---|---|---|---|
| Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 12 | -4.21 ± 1.33 | -9.68 ± 1.28 | -9.50 ± 1.34 | -10.15 ± 1.54 | -9.15 ± 1.19 |
Collected over Part A adverse event (AE) reporting: from first dose in Part A until end of Part A (EU participants continuing to Part B), or end of safety follow-up (US participants and EU participants not continuing to Part B); up to maximum of 23 weeks. Parts A+B AE reporting: from first dose until end of safety follow-up; up to maximum of 35 weeks. All-cause mortality: from enrollment until end of safety follow-up; up to maximum of 27 weeks in Part A or 39 weeks in Part B.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | 0/39 (0%) | 0/39 (0%) | 6/39 (15.4%) |
| Part A: Sonelokimab 60 mg Without Induction | 0/41 (0%) | 0/41 (0%) | 3/41 (7.3%) |
| Part A: Sonelokimab 60 mg With Induction | 0/41 (0%) | 1/41 (2.4%) | 5/41 (12.2%) |
| Part A: Sonelokimab 120 mg With Induction | 0/43 (0%) | 0/43 (0%) | 4/43 (9.3%) |
| Part A: Adalimumab 40 mg Q2W | 0/42 (0%) | 0/42 (0%) | 6/42 (14.3%) |
| Parts A+B: Total Sonelokimab 60 mg | 0/82 (0%) | 1/82 (1.2%) | 12/82 (14.6%) |
| Parts A+B: Total Sonelokimab 120 mg | 0/97 (0%) | 4/97 (4.1%) | 13/97 (13.4%) |
| Parts A+B: Total Adalimumab | 0/47 (0%) | 0/47 (0%) | 7/47 (14.9%) |
| Event | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Parts A+B: Total Sonelokimab 60 mg | Parts A+B: Total Sonelokimab 120 mg | Parts A+B: Total Adalimumab |
|---|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/39 | 0/41 | 1/41 | 0/43 | 0/42 | 1/82 | 0/97 | 0/47 |
| Pharyngeal abscessInfections and infestations | 0/39 | 0/41 | 0/41 | 0/43 | 0/42 | 0/82 | 1/97 | 0/47 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 0/41 | 0/41 | 0/43 | 0/42 | 0/82 | 1/97 | 0/47 |
| Radicular painNervous system disorders | 0/39 | 0/41 | 0/41 | 0/43 | 0/42 | 0/82 | 1/97 | 0/47 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/39 | 0/41 | 0/41 | 0/43 | 0/42 | 0/82 | 1/97 | 0/47 |
| Subcutaneous emphysemaSkin and subcutaneous tissue disorders | 0/39 | 0/41 | 0/41 | 0/43 | 0/42 | 0/82 | 1/97 | 0/47 |
| Event | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Parts A+B: Total Sonelokimab 60 mg | Parts A+B: Total Sonelokimab 120 mg | Parts A+B: Total Adalimumab |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/39 | 0/41 | 1/41 | 0/43 | 3/42 | 5/82 | 5/97 | 4/47 |
| Upper respiratory tract infectionInfections and infestations | 1/39 | 3/41 | 2/41 | 1/43 | 1/42 | 5/82 | 4/97 | 2/47 |
| Injection site erythemaGeneral disorders | 0/39 | 0/41 | 2/41 | 3/43 | 1/42 | 3/82 | 3/97 | 1/47 |
| PruritusSkin and subcutaneous tissue disorders | 2/39 | 0/41 | 0/41 | 0/43 | 0/42 | 0/82 | 0/97 | 0/47 |
| Aspartate aminotransferase increasedInvestigations | 2/39 | 0/41 | 0/41 | 0/43 | 1/42 | 0/82 | 1/97 | 1/47 |
The Full Analysis Set (FAS) included all randomized participants.
| Age, Continuous(years) | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Total |
|---|---|---|---|---|---|---|
| Mean | 47.0 ± 14.30 | 50.3 ± 13.87 | 47.5 ± 12.67 | 50.2 ± 10.30 | 47.9 ± 12.36 | 48.6 ± 12.70 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Total |
|---|---|---|---|---|---|---|
| Female | 19 | 21 | 20 | 21 | 21 | 102 |
| Male | 21 | 20 | 21 | 22 | 21 | 105 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 1 | 0 | 3 |
| Not Hispanic or Latino | 39 | 40 | 41 | 42 | 42 | 204 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Sonelokimab 60 mg Without Induction | Part A: Sonelokimab 60 mg With Induction | Part A: Sonelokimab 120 mg With Induction | Part A: Adalimumab 40 mg Q2W | Total |
|---|---|---|---|---|---|---|
| White | 39 | 40 | 41 | 43 | 41 | 204 |
| Not reported | 1 | 1 | 0 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2022 to primary completion in Sep 2023, 8 months.
Results were first posted in Sep 2026, 3 years after primary completion. A results delay was requested in Sep 2024.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonelokimab
MoonLake Immunotherapeutics AG